# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2014 Earnings Results

**Report date:** 2014-05-08 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2014

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.9%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.26 | N/A | +129.44% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of optimism regarding their earnings performance. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite lack of revenue details.

> They highlighted ongoing research and development efforts as a priority.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a strong EPS performance, significantly beating expectations. However, the stock fell by 1.9% following the announcement, likely due to the lack of revenue details and guidance. Investors may be cautious as they await more information on the company's future performance and strategic direction.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2014_